Advertisement

Alternative Therapies for Cytokine Storm Syndromes

  • Seza Ozen
  • Saliha Esenboga
Chapter

Abstract

Cytokine storm syndromes (CSS) are a challenge for physicians, both due to their aggressive nature and the need for tailored treatment for each patient. While hematopoietic stem cell transplantation (HSCT) has changed the fate of primary hemophagocytic lymphohistiocytosis (HLH), and biologics of macrophage activation syndrome (MAS)/secondary HLH, there is still a need for adjunctive treatment to better manage these patients. The principles of treatment are summarized in Table 1. This chapter discusses the available alternative treatments (biologics discussed in elsewhere). Unfortunately, except for corticosteroids, there is not a lot of solid evidence for the effectiveness of most of these agents. Biologics have become an essential part of the treatment in MAS. However for all these treatment modalities and corticosteroids, there is a lack of controlled studies to guide optimal dosage and duration of therapy.

References

  1. 1.
    Janka, G. E., & Lehmberg, K. (2013). Hemophagocytic lymphohistiocytosis: Pathogenesis and treatment. Hematology American Society of Hematology Education Program., 2013, 605–611.CrossRefGoogle Scholar
  2. 2.
    Tothova, Z., & Berliner, N. (2015). Hemophagocytic syndrome and critical illness: New insights into diagnosis and management. Journal of Intensive Care Medicine., 30(7), 401–412.CrossRefGoogle Scholar
  3. 3.
    Schulert, G. S., & Grom, A. A. (2014). Macrophage activation syndrome and cytokine-directed therapies. Best Practice & Research Clinical Rheumatology., 28(2), 277–292.CrossRefGoogle Scholar
  4. 4.
    Mouy, R., Stephan, J. L., Pillet, P., Haddad, E., Hubert, P., & Prieur, A. M. (1996). Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases. The Journal of Pediatrics., 129(5), 750–754.CrossRefGoogle Scholar
  5. 5.
    Ravelli, A., De Benedetti, F., Viola, S., & Martini, A. (1996). Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. The Journal of Pediatrics., 128(2), 275–278.CrossRefGoogle Scholar
  6. 6.
    Trottestam, H., Horne, A., Arico, M., Egeler, R. M., Filipovich, A. H., Gadner, H., et al. (2011). Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood, 118(17), 4577–4584.CrossRefGoogle Scholar
  7. 7.
    Henter, J. I., Horne, A., Arico, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., et al. (2007). HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer., 48(2), 124–131.CrossRefGoogle Scholar
  8. 8.
    Ravelli, A., Grom, A. A., Behrens, E. M., & Cron, R. Q. (2012). Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment. Genes and Immunity., 13(4), 289–298.CrossRefGoogle Scholar
  9. 9.
    Coca, A., Bundy, K. W., Marston, B., Huggins, J., & Looney, R. J. (2009). Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin. Clinical Immunology., 132(1), 10–18.CrossRefGoogle Scholar
  10. 10.
    Mahlaoui, N., Ouachee-Chardin, M., de Saint Basile, G., Neven, B., Picard, C., Blanche, S., et al. (2007). Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients. Pediatrics, 120(3), e622–e628.CrossRefGoogle Scholar
  11. 11.
    Ouachee-Chardin, M., Elie, C., de Saint Basile, G., Le Deist, F., Mahlaoui, N., Picard, C., et al. (2006). Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: A single-center report of 48 patients. Pediatrics, 117(4), e743–e750.CrossRefGoogle Scholar
  12. 12.
    Bennett, T. D., Fluchel, M., Hersh, A. O., Hayward, K. N., Hersh, A. L., Brogan, T. V., et al. (2012). Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis and Rheumatism, 64(12), 4135–4142.CrossRefGoogle Scholar
  13. 13.
    Sawhney, S., Woo, P., & Murray, K. J. (2001). Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Archives of Disease in Childhood., 85(5), 421–426.CrossRefGoogle Scholar
  14. 14.
    Wallace, C. A., & Sherry, D. D. (1997). Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis and Rheumatism, 40(10), 1852–1855.CrossRefGoogle Scholar
  15. 15.
    Chighizola, C. B., Ong, V. H., & Meroni, P. L. (2017). The use of cyclosporine A in rheumatology: A 2016 comprehensive review. Clinical Reviews in Allergy & Immunology., 52(3), 401–423.CrossRefGoogle Scholar
  16. 16.
    Bergsten, E., Horne, A., Arico, M., Astigarraga, I., Egeler, R. M., Filipovich, A. H., et al. (2017). Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long term results of the cooperative HLH-2004 study. Blood.Google Scholar
  17. 17.
    Takahashi, H., Tsuboi, H., Kurata, I., Takahashi, H., Inoue, S., Ebe, H., et al. (2015). Predictors of the response to treatment in acute lupus hemophagocytic syndrome. Lupus, 24(7), 659–668.CrossRefGoogle Scholar
  18. 18.
    Parodi, A., Davi, S., Pringe, A. B., Pistorio, A., Ruperto, N., Magni-Manzoni, S., et al. (2009). Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty-eight patients. Arthritis and Rheumatism, 60(11), 3388–3399.CrossRefGoogle Scholar
  19. 19.
    Gokce, M., Bilginer, Y., Besbas, N., Ozaltin, F., Cetin, M., Gumruk, F., et al. (2012). Hematological features of pediatric systemic lupus erythematosus: Suggesting management strategies in children. Lupus, 21(8), 878–884.CrossRefGoogle Scholar
  20. 20.
    Thompson, P. A., Allen, C. E., Horton, T., Jones, J. Y., Vinks, A. A., & McClain, K. L. (2009). Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer., 52(5), 621–625.CrossRefGoogle Scholar
  21. 21.
    Mouthon L, Lacroix-Desmazes S, Pashov A, Kaveri SV, Kazatchkine MD. (1999). [Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases]. La Revue De Medecine Interne. (20 Suppl 4):423s–430s.CrossRefGoogle Scholar
  22. 22.
    Guilpain, P., Chanseaud, Y., Tamby, M. C., Larroche, C., Guillevin, L., Kaveri, S. V., et al. (2004). Immunomodulatory effects of intravenous immunoglobulins. Presse Médicale, 33(17), 1183–1194.CrossRefGoogle Scholar
  23. 23.
    Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M., & Cron, R. Q. (2011). Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients. Rheumatology, 50(2), 417–419.CrossRefGoogle Scholar
  24. 24.
    Boom, V., Anton, J., Lahdenne, P., Quartier, P., Ravelli, A., Wulffraat, N. M., et al. (2015). Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatric Rheumatology Online Journal., 13, 55.CrossRefGoogle Scholar
  25. 25.
    Alvarez-Cardona, A., Rodriguez-Lozano, A. L., Blancas-Galicia, L., Rivas-Larrauri, F. E., & Yamazaki-Nakashimada, M. A. (2012). Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease. Journal of Clinical Immunology, 32(2), 207–211.CrossRefGoogle Scholar
  26. 26.
    Parekh, C., Hofstra, T., Church, J. A., & Coates, T. D. (2011). Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatric Blood & Cancer., 56(3), 460–462.CrossRefGoogle Scholar
  27. 27.
    Martin, A., Marques, L., Soler-Palacin, P., Caragol, I., Hernandez, M., Figueras, C., et al. (2009). Visceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease. The Pediatric Infectious Disease Journal., 28(8), 753–754.CrossRefGoogle Scholar
  28. 28.
    Emmenegger, U., Frey, U., Reimers, A., Fux, C., Semela, D., Cottagnoud, P., et al. (2001). Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. American Journal of Hematology., 68(1), 4–10.CrossRefGoogle Scholar
  29. 29.
    Larroche, C., Bruneel, F., Andre, M. H., Bader-Meunier, B., Baruchel, A., Tribout, B., et al. (2000). Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP. Annales De Medecine Interne., 151(7), 533–539.PubMedGoogle Scholar
  30. 30.
    Rajajee, S., Ashok, I., Manwani, N., Rajkumar, J., Gowrishankar, K., & Subbiah, E. (2014). Profile of hemophagocytic lymphohistiocytosis; efficacy of intravenous immunoglobulin therapy. Indian Journal of Pediatrics., 81(12), 1337–1341.CrossRefGoogle Scholar
  31. 31.
    Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly-Smith, L., Delaney, M., et al. (2016). Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The seventh special issue. Journal of Clinical Apheresis., 31(3), 149–162.PubMedGoogle Scholar
  32. 32.
    Matsumoto, Y., Naniwa, D., Banno, S., & Sugiura, Y. (1998). The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: Two case reports. Therapeutic Apheresis, 2(4), 300–304.CrossRefGoogle Scholar
  33. 33.
    Satomi, A., Nagai, S., Nagai, T., Niikura, K., Ideura, T., Ogata, H., et al. (1999). Effect of plasma exchange on refractory hemophagocytic syndrome complicated with myelodysplastic syndrome. Therapeutic Apheresis, 3(4), 317–319.CrossRefGoogle Scholar
  34. 34.
    Song, K. S., & Sung, H. J. (2006). Effect of plasma exchange on the circulating IL-6 levels in a patient with fatal hemophagocytic syndrome associated with bile ductopenia. Therapeutic Apheresis and Dialysis, 10(1), 87–89.CrossRefGoogle Scholar
  35. 35.
    Nakakura, H., Ashida, A., Matsumura, H., Murata, T., Nagatoya, K., Shibahara, N., et al. (2009). A case report of successful treatment with plasma exchange for hemophagocytic syndrome associated with severe systemic juvenile idiopathic arthritis in an infant girl. Therapeutic Apheresis and Dialysis, 13(1), 71–76.CrossRefGoogle Scholar
  36. 36.
    Demirkol, D., Yildizdas, D., Bayrakci, B., Karapinar, B., Kendirli, T., Koroglu, T. F., et al. (2012). Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: What is the treatment? Critical Care., 16(2), R52.CrossRefGoogle Scholar
  37. 37.
    Kaieda, S., Yoshida, N., Yamashita, F., Okamoto, M., Ida, H., Hoshino, T., et al. (2015). Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Modern Rheumatology., 25(6), 962–966.CrossRefGoogle Scholar
  38. 38.
    Mokrzycki, M. H., & Kaplan, A. A. (1994). Therapeutic plasma exchange: Complications and management. American Journal of Kidney Diseases, 23(6), 817–827.CrossRefGoogle Scholar
  39. 39.
    Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2005). The biology of CD20 and its potential as a target for mAb therapy. Current Directions in Autoimmunity., 8, 140–174.CrossRefGoogle Scholar
  40. 40.
    Chellapandian, D., Das, R., Zelley, K., Wiener, S. J., Zhao, H., Teachey, D. T., et al. (2013). Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. British Journal of Haematology., 162(3), 376–382.CrossRefGoogle Scholar
  41. 41.
    Park, H. S., Kim, D. Y., Lee, J. H., Lee, J. H., Kim, S. D., Park, Y. H., et al. (2012). Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: An analysis of treatment outcome and prognostic factors. Annals of Hematology., 91(6), 897–904.CrossRefGoogle Scholar
  42. 42.
    Jordan, M. B., Allen, C. E., Weitzman, S., Filipovich, A. H., & McClain, K. L. (2011). How I treat hemophagocytic lymphohistiocytosis. Blood, 118(15), 4041–4052.CrossRefGoogle Scholar
  43. 43.
    Behrens, E. M., & Koretzky, G. A. (2017). Review: Cytokine storm syndrome: looking toward the precision medicine era. Arthritis & Rheumatology., 69(6), 1135–1143.CrossRefGoogle Scholar
  44. 44.
    Kimby, E. (2005). Tolerability and safety of rituximab (MabThera). Cancer Treatment Reviews., 31(6), 456–473.CrossRefGoogle Scholar
  45. 45.
    Tesfa, D., & Palmblad, J. (2011). Late-onset neutropenia following rituximab therapy: Incidence, clinical features and possible mechanisms. Expert Review of Hematology., 4(6), 619–625.CrossRefGoogle Scholar
  46. 46.
    Hernandez-Campo, P. M., Almeida, J., Sanchez, M. L., Malvezzi, M., & Orfao, A. (2006). Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: A frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry Part B, Clinical Cytometry., 70(2), 71–81.CrossRefGoogle Scholar
  47. 47.
    Xia, M. Q., Tone, M., Packman, L., Hale, G., & Waldmann, H. (1991). Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. European Journal of Immunology, 21(7), 1677–1684.CrossRefGoogle Scholar
  48. 48.
    Strout, M. P., Seropian, S., & Berliner, N. (2010). Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nature Reviews Clinical Oncology., 7(7), 415–420.CrossRefGoogle Scholar
  49. 49.
    Gerard, L. M., Xing, K., Sherifi, I., Granton, J., Barth, D., Abdelhaleem, M., et al. (2012). Adult hemophagocytic lymphohistiocytosis with severe pulmonary hypertension and a novel perforin gene mutation. International Journal of Hematology., 95(4), 445–450.CrossRefGoogle Scholar
  50. 50.
    Marsh, R. A., Allen, C. E., McClain, K. L., Weinstein, J. L., Kanter, J., Skiles, J., et al. (2013). Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatric Blood & Cancer., 60(1), 101–109.CrossRefGoogle Scholar
  51. 51.
    Marsh, R. A., Jordan, M. B., Talano, J. A., Nichols, K. E., Kumar, A., Naqvi, A., et al. (2017). Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience. Pediatric Blood & Cancer. 64(4).CrossRefGoogle Scholar
  52. 52.
    Cooper, N., Rao, K., Gilmour, K., Hadad, L., Adams, S., Cale, C., et al. (2006). Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood, 107(3), 1233–1236.CrossRefGoogle Scholar
  53. 53.
    Marsh, R. A., Vaughn, G., Kim, M. O., Li, D., Jodele, S., Joshi, S., et al. (2010). Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood, 116(26), 5824–5831.CrossRefGoogle Scholar
  54. 54.
    Cooper, N., Rao, K., Goulden, N., Webb, D., Amrolia, P., & Veys, P. (2008). The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplantation., 42(Suppl 2), S47–S50.CrossRefGoogle Scholar
  55. 55.
    Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., et al. (2016). Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 127(13), 1666–1675.CrossRefGoogle Scholar
  56. 56.
    Maschalidi, S., Sepulveda, F. E., Garrigue, A., Fischer, A., & de Saint Basile, G. (2016). Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood, 128(1), 60–71.CrossRefGoogle Scholar
  57. 57.
    Sin, J. H., & Zangardi, M. L. (2017). Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. Hematology/Oncology and Stem Cell Therapy.Google Scholar
  58. 58.
    Slostad, J., Hoversten, P., Haddox, C. L., Cisak, K., Paludo, J., & Tefferi, A. (2018). Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. American Journal of Hematology., 93(2), E47–E49.CrossRefGoogle Scholar
  59. 59.
    Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., et al. (2012). Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. The New England Journal of Medicine, 367(6), 495–507.CrossRefGoogle Scholar
  60. 60.
    Naithani, R., Asim, M., Naqvi, A., Weitzman, S., Gassas, A., Doyle, J., et al. (2013). Increased complications and morbidity in children with hemophagocytic lymphohistiocytosis undergoing hematopoietic stem cell transplantation. Clinical Transplantation, 27(2), 248–254.CrossRefGoogle Scholar
  61. 61.
    Ohga, S., Kudo, K., Ishii, E., Honjo, S., Morimoto, A., Osugi, Y., et al. (2010). Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatric Blood & Cancer, 54(2), 299–306.Google Scholar
  62. 62.
    Janka, G. E. (1983). Familial hemophagocytic lymphohistiocytosis. European Journal of Pediatrics., 140(3), 221–230.CrossRefGoogle Scholar
  63. 63.
    Fischer, A., Cerf-Bensussan, N., Blanche, S., Le Deist, F., Bremard-Oury, C., Leverger, G., et al. (1986). Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. The Journal of Pediatrics., 108(2), 267–270.CrossRefGoogle Scholar
  64. 64.
    Horne, A., Janka, G., Maarten Egeler, R., Gadner, H., Imashuku, S., Ladisch, S., et al. (2005). Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. British Journal of Haematology., 129(5), 622–630.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Seza Ozen
    • 1
  • Saliha Esenboga
    • 1
  1. 1.Department of PediatricsHacettepe UniversityAnkaraTurkey

Personalised recommendations